3-氯喹喔啉-2-甲酸乙酯 | 49679-45-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3-氯喹喔啉-2-甲酸乙酯
• 中文别名: 3-氯喹喔啉-2-羧酸乙酯
• 英文名称: ethyl 3-chloroquinoxaline-2-carboxylate
• 英文别名: 2-Chloro-3-quinoxalinecarboxylic acid ethyl ester
• CAS: 49679-45-0
• 化学式: C₁₁H₉ClN₂O₂
• mdl: MFCD09953512
• 分子量: 236.658
• InChiKey: YGTZHKWLTOJGOI-UHFFFAOYSA-N

物化性质

• 熔点：
  41-42℃
• 沸点：
  330.7±37.0 °C(Predicted)
• 密度：
  1.341

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-chloroquinoxaline-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-chloroquinoxaline-2-carboxylate
CAS number: 49679-45-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H9ClN2O2
Molecular weight: 236.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯喹喔啉-2-甲酸乙酯 在 乙醇 、 氨 作用下， 生成 3-氨基喹喔啉-2-甲酰胺
  参考文献：
  名称：

  Gowenlock et al., Journal of the Chemical Society, 1945, p. 622,625

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 2-quinoxalinecarboxylate 4-oxide 在 三氯氧磷 作用下， 生成 3-氯喹喔啉-2-甲酸乙酯
  参考文献：
  名称：

  Gowenlock et al., Journal of the Chemical Society, 1945, p. 622,625

  摘要：

  DOI：

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• [EN] BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS<br/>[FR] DÉRIVÉS BENZODIAZÉPINE UTILISÉS COMME INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
  申请人：ENANTA PHARM INC

  公开号：WO2017015449A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药：这些化合物抑制呼吸道合胞病毒（RSV）。本发明还涉及包含上述化合物的药物组合物，用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• Quinoalinyl esters of carbamimidothioic acids
  申请人：American Home Products Corporation

  公开号：US04349674A1

  公开（公告）日：1982-09-14

  The compounds of this invention are designated as quinoxalinyl esters of carbamimidothioic acids and exhibit the pharmacological properties of preventing gastric ulcers, reducing gastric secretions and lowering blood pressure. The compounds have the following structural formula: ##STR1## in which Q is hydrogen or nitro; A is hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, carbomethoxy, carbethoxy, carbopropoxy, carbisopropoxy, carbobutoxy, carbisobutoxy, or carbo-t-butoxy; and R.sup.1, R.sup.2, and R.sup.3 are, independently, hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl, allyl, or R.sup.1 and R.sup.3 may be concatenated with a carbon chain having 4 carbon atoms with R.sup.2 then being hydrogen; except that, when A and Q are hydrogen, R.sup.1, R.sup.2, and R.sup.3 may not all be hydrogen; and with the further exception that, where A is methyl and R.sup.1, R.sup.2, and Q are all hydrogen, R.sup.3 may not be ethyl; or a pharmaceutically acceptable salt thereof.

  本发明的化合物被命名为喹诺克林基羧酸酰胺基硫酸酯，并具有预防胃溃疡、减少胃分泌和降低血压的药理性质。这些化合物的结构公式如下：##STR1## 其中Q是氢或硝基；A是氢、甲基、乙基、丙基、异丙基、正丁基、甲氧基羰基、乙氧基羰基、丙氧基羰基、异丙氧基羰基、丁氧基羰基、异丁氧基羰基或叔丁氧基羰基；R1、R2和R3独立地为氢、甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、烯丙基，或者R1和R3可以与一个有4个碳原子的碳链连接，此时R2为氢；除了当A和Q都是氢时，R1、R2和R3不能都是氢；以及进一步的例外是，当A是甲基且R1、R2和Q都是氢时，R3不能是乙基；或其药用可接受的盐。
• Synthesis and evaluation of in vitro antiproliferative activity of new ethyl 3-(arylethynyl)quinoxaline-2-carboxylate and pyrido[4,3- b ]quinoxalin-1(2 H )-one derivatives
  作者：Majdi Hajri、Marie-Anne Esteve、Omar Khoumeri、Raoudha Abderrahim、Thierry Terme、Marc Montana、Patrice Vanelle

  DOI：10.1016/j.ejmech.2016.10.025

  日期：2016.11

  We report a novel series of quinoxaline derivatives from which agents with antiproliferative activity have been identified. Two ethyl 3-(arylethynyl)quinoxaline-2-carboxylates demonstrated substantial antiproliferative activity against both human non-small cell lung carcinoma (A549) and glioblastoma (U87-MG) cell lines. Pyrido[4,3-b]quinoxalin-1(2H)-ones demonstrated poor activity against A549 and

  我们报告了一系列新的喹喔啉衍生物，已从中确定了具有抗增殖活性的药物。两种3-（芳基乙炔基）喹喔啉-2-羧酸乙酯对人非小细胞肺癌（A549）和胶质母细胞瘤（U87-MG）细胞系均显示出显着的抗增殖活性。Pyrido [4,3 - b ] quinoxalin-1（2 H）-ones对A549和U87-MG细胞系的活性较弱。3-（芳基乙炔基）喹喔啉-2-羧酸乙酯系列中的三种衍生物显示出显着的抗增殖活性。事实证明，对于A549和U87-MG细胞系，芳基乙炔基衍生物2a和2d具有最大的细胞毒性，IC 50值为3.3μM。
• Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides
  作者：Radhakrishnan Mahesh、Thangaraj Devadoss、Dilip Kumar Pandey、Shvetank Bhatt

  DOI：10.1016/j.bmcl.2010.12.064

  日期：2011.2

  A novel series of 3-ethoxyquinoxalin-2-carboxamides were designed as per the pharmacophoric requirements of 5-HT3 receptor antagonist using ligand-based approach. The desired carboxamides were synthesized from the key intermediate, 3-ethoxyquinoxalin-2-carboxylic acid by coupling with appropriate amines in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) and 1-

  根据5-HT 3受体拮抗剂的药理学要求，使用基于配体的方法设计了一系列新的3-乙氧基喹喔啉-2-羧酰胺。在1-（3-二甲基氨基丙基）-3-乙基碳二亚胺盐酸盐（EDC·HCl）和1-羟基苯并三唑（HOBt）存在下，通过与适当的胺偶联，由关键中间体3-乙氧基喹喔啉-2-羧酸合成所需的羧酰胺）。在豚鼠回肠纵向肌肉肌层神经丛制备物中，针对5-HT 3激动剂2-甲基-5-HT评估了5-HT 3受体拮抗作用，该激动剂以p A 2值的形式表达。化合物6h发现（3-乙氧基喹喔啉-2-基）（4-甲基哌嗪-1-基）甲酮是活性最高的化合物，其p A 2值为7.7。在强制游泳试验中，与赋形剂处理组相比，具有较高p A 2值的化合物表现出良好的抗抑郁样活性，而具有较低p A 2值的化合物没有表现出活性。